Domestic companies have no choice but to silently wait until NOACs’ patent expiration

Although domestic pharmaceutical companies have tried to enter the market of novel oral anticoagulant(NOAC) generics, they have kept failed.

NOACs, which were confirmed to be used as a primary therapy with efficacy of preventing atrial fibrillation last year, have certainly become the new trend in the anticoagulant market as a substitute of warfarin.

According to collective prescriptions up t...